Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

SCHMIDT ERIC THOMAS

2. Date of Event Requiring Statement (MM/DD/YYYY) 12/19/2019

3. Issuer Name and Ticker or Trading Symbol

RELMADA THERAPEUTICS, INC. [RLMD]

(Last) (First) (Middle)

C/O RELMADA THERAPEUTICS, INC., 880 THIRD AVENUE, 12TH FLOOR

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)

(Street)

NY, NY 10022

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	55000	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Options to purchase common stock	12/19/2019 ⁽¹⁾	12/19/2029	Common Stock	200000	$43.47	D
Options to purchase common stock	5/14/2019	5/14/2024	Common Stock	12500	$9.00	D
Options to purchase common stock	12/3/2018	12/3/2023	Common Stock	32500	$6.00	D

Explanation of Responses:
(1)	Options granted on December 19, 2019 to purchase an aggregate of 200,000 shares of common stock. A total of 25% of the options will vest one year from the grant date, and the remaining 75% shall vest in equal quarterly increments of 6.25% of the initial option grant over the following three year period.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
SCHMIDT ERIC THOMAS C/O RELMADA THERAPEUTICS, INC. 880 THIRD AVENUE, 12TH FLOOR NY, NY 10022	X

Signatures
/s/ Eric Schmidt		12/23/2019
^**Signature of Reporting Person		Date